| Gene symbol | ANGPT2 | Synonyms | AGPT2, ANG2, LMPHM10 | Type of gene | protein-coding |
| Chromosome | 8 | Map location | 8p23.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PertOrg | ||||
| Description | angiopoietin 2 | ||||
| Gene symbol | VEGFA | Synonyms | L-VEGF, MVCD1, VEGF, VPF | Type of gene | protein-coding |
| Chromosome | 6 | Map location | 6p21.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | vascular endothelial growth factor A | ||||
| GTO ID | GTC3478 |
| Trial ID | NCT05903794 |
| Disease | Age-Related Macular Degeneration |
| Altered gene | VEGFA|ANGPT2 |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | EXG102-031 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | An Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With EXG102-031 in Participants With Neovascular Age-related Macular Degeneration. |
| Year | 2023 |
| Country | United States |
| Company sponsor | Exegenesis Bio |
| Other ID(s) | EXG102-031 (211) |
| Vector information | |||||||||
|
|||||||||
| Cohort 1 | |||||||
|
|||||||